Searched for: person:sarkas04
in-biosketch:true
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes
Zhang, Xiaofei; Lan, Ruoxin; Liu, Yongjun; Pillarisetty, Venu G; Li, Danting; Zhao, Chaohui L; Sarkar, Suparna A; Liu, Weiguo; Hanna, Iman; Gupta, Mala; Hajdu, Cristina; Melamed, Jonathan; Shusterman, Michael; Widmer, Jessica; Allendorf, John; Liu, Yao-Zhong
Neoadjuvant therapy (NAT) is increasingly being used for pancreatic ductal adenocarcinoma (PDAC). This study investigates how NAT differentially impacts PDAC's carcinoma cells and the tumor microenvironment (TME). Spatial transcriptomics was used to compare gene expression profiles in carcinoma cells and the TME of 23 NAT-treated versus 13 NAT-naïve PDACs. Findings were validated by single-nucleus RNA sequencing (snRNA-seq) analysis. NAT induces apoptosis and inhibits proliferation of carcinoma cells and coordinately upregulates multiple complement genes (C1R, C1S, C3, C4B and C7) within the TME. Higher TME complement expression following NAT is associated with increased immunomodulatory and neurotrophic cancer-associated fibroblasts (CAFs); more CD4+ T cells; reduced immune exhaustion gene expression, and improved overall survival. snRNA-seq analysis demonstrates C3 complement is mainly upregulated in CAFs. These findings suggest that local complement dynamics could serve as a novel biomarker for prognosis, evaluating treatment response, and guiding therapeutic strategies in NAT-treated PDAC patients.
PMID: 40032924
ISSN: 2397-768x
CID: 5842672
Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal Adenocarcinoma
Zhang, Xiaofei; Lan, Ruoxin; Liu, Yongjun; Pillarisetty, Venu G; Li, Danting; Zhao, Chaohui L; Sarkar, Suparna A; Liu, Weiguo; Hanna, Iman; Gupta, Mala; Hajdu, Cristina; Melamed, Jonathan; Shusterman, Michael; Widmer, Jessica; Allendorf, John; Liu, Yao-Zhong
BACKGROUND/UNASSIGNED:Neoadjuvant therapy (NAT) is increasingly being used for pancreatic ductal adenocarcinoma (PDAC) treatment. However, its specific effects on carcinoma cells and the tumor microenvironment (TME) are not fully understood. This study aims to investigate how NAT differentially impacts PDAC's carcinoma cells and TME. METHODS/UNASSIGNED:Spatial transcriptomics was used to compare gene expression profiles in carcinoma cells and the TME between 23 NAT-treated and 13 NAT-naïve PDAC patients, correlating with their clinicopathologic features. Analysis of an online single-nucleus RNA sequencing (snRNA-seq) dataset was performed for validation of the specific cell types responsible for NAT-induced gene expression alterations. RESULTS/UNASSIGNED:T cells, monocytes, and mast cells; and reduced immune exhaustion gene expression. snRNA-seq analysis demonstrates C3 complement was specifically upregulated in CAFs but not in other stroma cell types. CONCLUSIONS/UNASSIGNED:NAT can enhance complement production and signaling within the TME, which is associated with reduced immunosuppression in PDAC. These findings suggest that local complement dynamics could serve as a novel biomarker for prognosis, evaluating treatment response and resistance, and guiding therapeutic strategies in NAT-treated PDAC patients.
PMCID:11118688
PMID: 38798691
ISSN: 2693-5015
CID: 5676282
Intestinal Spirochetosis: To Treat or Not to Treat [Case Report]
Ho, Kimberly; Xu, Joseph; Katz, Seymour; Sarkar, Suparna A; Mujeeb Ullah, Ateeqa
Spirochete colonization of the gastrointestinal tract is a poorly understood phenomenon presenting with varying signs and symptoms. Due to the lack of a unified approach and its varying presentations, the management decision for intestinal spirochetosis (IS) has always been challenging. While metronidazole is the commonly preferred antimicrobial treatment, it remains unclear if therapeutic intervention is indicated for everyone, especially asymptomatic patients. We present three patients, diagnosed with IS. They presented with varying demographics, clinical presentations, and past medical histories and underwent different clinical managements. Our decisions for treatment not only included presenting symptoms but also factors like history of pre-existing gastrointestinal diseases, age, and immune status.
PMCID:10904080
PMID: 38425640
ISSN: 2168-8184
CID: 5722822
Pulmonary Crohn's Disease Masquerading as Lymphoma [Case Report]
Beaty, William; Katragadda, Anila; Condos, Rany; Dane, Bari; Sarkar, Suparna; Shaffer, Emily; Chang, Shannon
Although extraintestinal manifestations of inflammatory bowel disease (IBD) are common, pulmonary IBD is extremely rare. Owing to its nonspecific clinical, radiologic, and pathologic features, pulmonary IBD is difficult to diagnose and may mimic more concerning disease processes. We present a rare case of a patient with known Crohn's disease whose initial presentation was highly suspicious for malignancy before further investigation revealed pulmonary IBD.
PMCID:10766257
PMID: 38179265
ISSN: 2326-3253
CID: 5624152
Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis
Chang, Shannon; Hong, Simon; Hudesman, David; Remzi, Feza; Sun, Katherine; Cao, Wenqing; Tarik Kani, H; Axelrad, Jordan; Sarkar, Suparna A
BACKGROUND:The prognostic significance of histology in ileal pouch-anal anastomosis (IPAA) remains unclear. The aim of this study was to evaluate if histologic variables are predictive of IPAA clinical outcomes and healthcare utilization. METHODS:This was a retrospective cohort study of patients with IPAA undergoing surveillance pouchoscopy at a tertiary care institution. Pouch body biopsies were reviewed by gastrointestinal pathologists, who were blinded to clinical outcomes, for histologic features of acute or chronic inflammation. Charts were reviewed for clinical outcomes including development of acute pouchitis, chronic pouchitis, biologic or small molecule initiation, hospitalizations, and surgery. Predictors of outcomes were analyzed using univariable and multivariable logistic and Cox regression. RESULTS:A total of 167 patients undergoing surveillance pouchoscopy were included. Polymorphonuclear leukocytes (odds ratio [OR], 1.67), ulceration and erosion (OR, 2.44), chronic inflammation (OR, 1.97), and crypt distortion (OR, 1.89) were associated with future biologic or small molecule initiation for chronic pouchitis. Loss of goblet cells was associated with development of chronic pouchitis (OR, 4.65). Pyloric gland metaplasia was associated with hospitalizations (OR, 5.24). No histologic variables were predictive of development of acute pouchitis or surgery. In an exploratory subgroup analysis of new IPAA (<1 year), loss of goblet cells was associated with acute pouchitis (OR, 14.86) and chronic pouchitis (OR, 12.56). Pyloric gland metaplasia was again associated with hospitalizations (OR, 13.99). CONCLUSIONS:Histologic findings may be predictive of IPAA outcomes. Pathologists should incorporate key histologic variables into pouchoscopy pathology reports. Clinicians may need to more closely monitor IPAA patients with significant histologic findings.
PMID: 36702534
ISSN: 1536-4844
CID: 5419702
Histologic Inflammation can Predict Future Clinical Relapse in Ulcerative Colitis Patients in Endoscopic Remission
George, Lauren A; Feldman, Harris T; Alizadeh, Madeline; Abutaleb, Ameer; Zullow, Samantha; Hine, Ashley; Stashek, Kristen; Sarkar, Suparna; Sun, Katherine; Hudesman, David; Axelrad, Jordan; Cross, Raymond K
BACKGROUND/UNASSIGNED:In ulcerative colitis (UC), endoscopic improvement, defined as a Mayo Endoscopic Score (MES) of 0 or 1, is a target of treatment. The aim of our study was to evaluate the risk of clinical relapse between patients with an MES of 0 or 1 and determine if histologic activity using the Robarts Histopathologic Index (RHI) was predictive of clinical relapse. METHODS/UNASSIGNED:UC patients with an MES score of 0 or 1, no prior colectomy, and at least 1 year of outpatient follow-up after colonoscopy were included. Demographic, clinical characteristics, and clinical relapse were retrospectively collected. Biopsy specimens were read by a gastrointestinal pathologist. Primary outcome was defined as a composite of relapse requiring change in medical therapy, new steroid use, UC-related hospitalization, and/or colectomy. RESULTS/UNASSIGNED: = .008). CONCLUSIONS/UNASSIGNED:UC patients with endoscopic improvement have a high rate of clinical relapse over time. Histologic activity is a predictor of clinical relapse.
PMCID:10599395
PMID: 37886705
ISSN: 2631-827x
CID: 5736342
Persistence of SARS-CoV-2 RNA in Gastrointestinal Tissues from COVID-19 Patients [Meeting Abstract]
Saberi, Shahram; Hoskoppal, Deepthi; Chiriboga, Luis; Zhao, Chaohui; Sarkar, Suparna; Cao, Wenqing (Wendy)
ISI:000990969801149
ISSN: 0023-6837
CID: 5525702
Microthrombi in Gastrointestinal Tissues Associated with Local SARS-CoV-2 Infection in COVID-19 Patients [Meeting Abstract]
Hoskoppal, Deepthi; Saberi, Shahram; Chiriboga, Luis; Zhao, Chaohui; Sarkar, Suparna; Cao, Wenqing (Wendy)
ISI:000990969801092
ISSN: 0023-6837
CID: 5525692
Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation
Lee, Brian T; Ganjoo, Naveen; Fiel, M Isabel; Hechtman, Jackie F; Sarkar, Suparna A; Kim-Schluger, Leona; Florman, Sander S; Schiano, Thomas D
OBJECTIVES/OBJECTIVE:Donor-derived malignancy of the liver allograft is a rare but serious condition in the setting of necessary immunosuppression. Retransplantation after abrupt immunosuppression cessation has been performed with durable cancer-free survival. METHODS:We present 2 cases of patients with donor-derived malignancy who were treated with complete immunosuppression cessation, which induced rapidly progressive liver allograft rejection and failure, with a need for subsequent retransplantation. We reviewed all serial liver biopsies and explants from both patients and performed C4d immunostaining. RESULTS:Initial explants of both patients showed severe allograft rejection, with unusual features of sinusoidal obstruction syndrome and C4d positivity. Malignant tumors in the explants were necrotic, related to rejection of donor-derived cancer cells and tissue. Follow-up of both patients has shown long-term cancer-free survival but issues with recurrent allograft failure requiring a third transplant. The reasons for retransplantation in both cases were related to allograft failure from antibody-mediated rejection. CONCLUSIONS:Clinicians should be aware of a potentially increased risk of rejection and recurrent allograft failure when strategizing treatment of donor-derived malignancy with immunosuppression cessation and retransplantation.
PMID: 35285881
ISSN: 1943-7722
CID: 5182412
Primary small bowel adenocarcinoma with loss of nuclear expression of PMS2 after resection of mucinous cholangiocarcinoma [Case Report]
Mujeeb Ullah, Ateeqa; Jaysing, Anna; Hashmi, Hassan Raza; Sohail, Amir Humza; Li, Wendi; Allendorf, John D; Sarkar, Suparna A
Mucinous cholangiocarcinoma is an extremely rare form of intrahepatic cholangiocarcinoma that has been characterized by rapid growth, widespread metastasis and poor prognosis. These tumors have been shown to be a part of the Lynch syndrome tumor spectrum, however, the role of DNA mismatch repair (MMR) deficiency in their development is poorly understood. We present the case of a 74-year-old male with cholangiocarcinoma, who underwent Roux-en-Y hepaticojejunostomy and extended left hepatectomy and was diagnosed with a primary small bowel adenocarcinoma 2Â years later. Immunohistochemistry testing for mismatch repair proteins was significant for the loss of nuclear expression of PMS2. Taken together, the cause of both the mucinous cholangiocarcinoma and primary small bowel adenocarcinoma with PMS2 loss in the patient presented here is likely genetic, suggestive of a cancer syndrome.
PMCID:8803414
PMID: 35111293
ISSN: 2042-8812
CID: 5153712